Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 20/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8327024 | 1.00 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13840028 | 0.88 | DRD4 (0.52) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4026839 | 0.87 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4031677 | 0.87 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1809499 | 0.87 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1502307 | 0.87 | DRD4 (0.66) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4022879 | 0.87 | DRD4 (0.66) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4024819 | 0.87 | DRD4 (0.66) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4483054 | 0.86 | DRD4 (0.67) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6165547 | 0.86 | DRD4 (0.67) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1919884-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007011292-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | CCR3, CCR1, CCR5 | DRD4 1107/4885CYP1A2 1845/4885CYP3A4 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.